Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 6, 2008, Pages 593-599

  Maxwell, W Andrew ^a   Reiser, Harvey J ^b   Stewart, Robert H ^c   Cavanagh, H Dwight ^d   Walters, Thomas R ^e   Sager, Dana P ^f   Meuse, Patricia A ^f   Maguen, Ezra ^g   Sall, Kenneth ^g   Stewart, W Colby ^g   Trocme, Stefan D ^g   Weinstein, Arthur J ^g  

^a California Eye Institute   (United States)

^b Eye Care Specialists   (United States)

^c Houston Eye Associates   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Texan Eye Care   (United States)

^f ALCON RESEARCH LTD   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEPAFENAC; PLACEBO;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CHOROID DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISCOMFORT; EYE INFLAMMATION; EYE PAIN; FEMALE; HUMAN; HYPHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PAIN ASSESSMENT; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; CATARACT EXTRACTION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EYE DISEASES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PAIN, POSTOPERATIVE; PHENYLACETATES; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 57549117827     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0023     Document Type: Article

References (15)

1. Ke, T.L., Graff, G., Spellman, J.M., et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 24:371-384, 2000.
2. Lindstrom, R., and Kim, T. Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr. Med. Res. Opin. 22, 397-404; Review. Erratum in: Curr. Med. Res. Opin. 22:1237, 2006.
3. Gamache, D.A., Graff, G., Brady, M.T., et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24: 357-370, 2000.
4. Kapin, M.A., Yanni, J.M., Brady, M.T., et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 27:381-391, 2003.
5. Walters, T.R., Raizman, M., Ernest, P., et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J. Cataract Refract. Surg. 33:1539-1545, 2007.
6. Dubois, R.N., Abramson, S.B., Crofford, L., et al. Cyclo-oxygenase in biology and disease. FASEB J. 12:1063-1073, 1998.
7. Roberts, C.W. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 103:636-639, 1996.
8. Heier, J.S. Preventing postcataract extraction CME: Early identification of patients at risk and prophylactic treatment may avert vision loss. Ophthalmol. Manage. 63-72, 2004.
9. O'Brien, T.P. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr. Med. Res. Opin. 21:1131-1137, 2005.
10. NEVANAC® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc., 2005.
11. Flach, A.J., Lavelle, C.J., Olander, K.W., et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 95:1279-1284, 1988.
12. Laurell, C.G., and Zetterstrom, C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br. J. Ophthalmol. 86:1380-1384, 2002.
13. Shepherd, W.F., Fsadni, M.G., and Raj, P.S. A clinical evaluation of diclofenac-gentamicin combination eye drops in the control of inflammation after cataract surgery. The Diclofenac-Gentamicin versus the Gentamicin Study Group. Ocul. Immunol. Inflamm. 6:13-18, 1998.
14. Price, M.O., and Price, F.W. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr. Med. Res. Opin. 20:2015-2019, 2004.
15. Donnenfeld, E.D., Holland, E.J., Stewart, R.H., et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 114:1653-1662, 2007.